Magnetic resonance spectroscopy in epilepsy
Briellmann, Regula S., Wellard, R. Mark, & Jackson, Graeme D. (2005) Magnetic resonance spectroscopy in epilepsy. In Gillard, Jonathan H., Waldman, Adam D., & Barker, Peter B. (Eds.) Clinical MR neuroimaging diffusion, perfusion and spectroscopy. Cambridge University Press, Cambridge, pp. 488-508.
Key points • The clinical aims of MR spectroscopy (MRS) in seizure disorders are to help identify, localize and characterize epileptogeic foci. • Lateralizing MRS abnormalities in temporal lobe epilepsy (TLE) may be used clinically in combi- nation with structural and T2measurements. • Characteristic metabolite abnormalities are decreased N-acetylaspartate (NAA) with increased choline (Cho) and myoinositol (mI) (short-echo time). • Contralateral metabolite abnormalities are frequently seen in TLE, but are of uncertain significance. • In extra-temporal epilepsy, metabolite abnor- malities may be seen where MR imaging (MRI) is normal; but may not be sufficiently local- ized to be useful clinically. • MRS may help to characterize epileptogenic lesions visible on MRI (aggressive vs. indolent neoplastic, dysplasia). • Spectral editing techniques are required to evaluate specific epilepsy-relevant metabolites (e.g. -aminobutyric acid (GABA)) which may be useful in drug development and evaluation. • MRS with phosphorus (31P) and other nucleii probe metabolism of epilepsy, but are less useful clinically.
Impact and interest:
Citation counts are sourced monthly from and citation databases.
These databases contain citations from different subsets of available publications and different time periods and thus the citation count from each is usually different. Some works are not in either database and no count is displayed. Scopus includes citations from articles published in 1996 onwards, and Web of Science® generally from 1980 onwards.
Citations counts from theindexing service can be viewed at the linked Google Scholar™ search.
Repository Staff Only: item control page